Inclusion Criteria:

          -  Age ≥18 years

          -  For RMC-4630 + Cobimetinib only - Participants who have advanced solid tumors that
             have failed, are intolerant to, or are considered ineligible for standard of care
             anti-cancer treatments including approved drugs for oncogenic drivers in their tumor
             type.

          -  For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not
             amenable to curative surgery or radiotherapy

          -  For RMC-4630 + Cobimetinib only - Participants must have one of the following
             genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or
             NF1 LOF mutations

          -  For RMC-4630 + Osimertinib only - Evidence of radiological documentation of
             progression with osimertinib monotherapy or an osimertinib containing regimen.
             Participants should not be considered a current candidate for 1st generation EGFR
             TKI's by the investigator.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

          -  Adequate hematological, hepatic, and renal function

          -  Capable of giving signed informed consent form (ICF). Willing and able to compile with
             study requirements and restrictions

          -  Life expectancy >12 weeks

          -  Female of childbearing potential and males with partners of childbearing potential
             must comply with effective contraception criteria .

        Exclusion Criteria:

          -  Primary central nervous system (CNS) tumors.

          -  Known or suspected leptomeningeal or brain metastases or spinal cord compression.

          -  For RMC-4630 + osimertinib arm only - Known or suspected Small cell, squamous, or
             pleomorphic lung transformations

          -  Clinically significant cardiac disease

          -  Active, clinically significant interstitial lung disease or pneumonitis

          -  History or current evidence of retinal pigment epithelial detachment (RPED), central
             serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or
             RVO

          -  Known HIV infection or active/chronic hepatitis B or C infection.

          -  Any other unstable or clinically significant concurrent medical condition that would,
             in the opinion of the investigator, jeopardize the safety of a participant, impact
             their expected survival through the end of the study participation, and/or impact
             their ability to comply with the protocol prior/concomitant therapy

          -  Females who are pregnant or breastfeeding